Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer-Reference-Cited by-同舟云学术

Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer

Published:2024-05-14 Issue:9 Volume:51 Page:2848-2849
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Di Santo Gianpaolo,Santo Giulia,Martinovic Vladan,Wolf Dominik,Pircher Andreas,Sviridenko Anna,Löffler-Ragg Judith,von Guggenberg Elisabeth,Virgolini Irene^ORCID

Funder

University of Innsbruck and Medical University of Innsbruck

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00259-024-06749-z.pdf

Reference5 articles.

1. Reubi JC, Schaer JC, Waser B. Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57(7):1377–86.

2. Reubi JC. Targeting CCK receptors in human cancers. Curr Top Med Chem. 2007;7:1239–42. https://doi.org/10.2174/156802607780960546.

3. von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. Update on preclinical development and clinical translation of cholecystokinin-2 receptor targeting radiopharmaceuticals. Cancers. 2021;13:5776. https://doi.org/10.3390/cancers13225776.

4. Klingler M, Summer D, Rangger C, et al. DOTA-MGS5, a new cholecystokinin-2 receptor-targeting peptide analog with an optimized targeting profile for theranostic use. J Nucl Med. 2019;60(7):1010–6. https://doi.org/10.2967/jnumed.118.221283.

5. Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and pd-l1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021. https://doi.org/10.1200/JCO.20.01055.